VivoSeq
Other

Secondary AML

1

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Secondary AML is an early-stage landscape with 1 program across 3 companies. The most active players are Aspera Biomedicines, Inc., Xanthus Pharmaceuticals, Inc., Jazz Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Aspera Biomedicines, Inc.

1 program

Phase 1X

Xanthus Pharmaceuticals, Inc.

0 programs

PreclinicalJazz Pharmaceuticals logo

Jazz Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

Rebecsinib

Aspera Biomedicines, Inc.

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

4

clinical trials

Completed2 · 50%
Approved for marketing1 · 25%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Amonafide in Combination With Cytarabine in Secondary AML
Completed·XXanthus Pharmaceuticals, Inc.·Phase 2·NCT00273884·80 enrolled
EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML
Approved for marketing·Jazz Pharmaceuticals logoJazz Pharmaceuticals·N/A·NCT02533115
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML
Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT04620681·19 enrolled
A Phase 1 Study of Rebecsinib, a Spliceosome Modulator That Inhibits ADAR1, in Patients With Relapsed or Refractory Secondary Acute Myeloid Leukemia or Higher-Risk Myelofibrosis
Recruiting·AAspera Biomedicines, Inc.·Phase 1·NCT07250646·28 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)